
AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical…

AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical…
Location: Paris and London
Founding year: 2019
Core tech: Quantum-inspired physics + generative AI for drug discovery
Employee count: 83
Recent funding: Multiple 2024 rounds; cumulative funding reported ~€95M–$100M+
Small-molecule drug discovery and early-stage candidate design (including immuno-oncology).
2019
Biotechnology Research
€30 million
January 2024 raise reported as €30M
$38 million
December 2024 raise reported as $38M; pushed cumulative funding past ~$100M in coverage
“Participation from Cathay Innovation, Wendel, Bpifrance (France 2030 programs), Eurazeo and Elaia reported”
| Company |
|---|
About AQEMIA AQEMIA is a drug invention company dedicated to creating entirely new medicines to address major unmet medical needs. At the core of our mission is QEMI , our proprietary molecule-invention platform, which uniquely combines cutting-edge science with advanced technology. Powered by physics-based modeling, statistical mechanics, and generative AI, QEMI allows our teams to design novel drug candidates from first principles.
What makes AQEMIA different is our commitment to true innovation: our research is dedicated to the invention of new molecular entities, not the refinement of existing ones. We focus on inventing never-before-seen molecules , without relying on experimental data, and advancing them into a growing pipeline of proprietary programs and strategic partnerships with leading pharmaceutical companies.
Our most advanced preclinical programs are currently in vivo optimization , targeting diseases still waiting for effective treatments, offering our teams the opportunity to work on science that can make a real difference in people’s lives.
For more information, visit AQEMIA.com and our LinkedIn.
About Our Team AQEMIA brings together a diverse, multidisciplinary team of 65+ professionals based in Paris and London. Our scientists and engineers, including chemists, physicists, machine learning experts, and software engineers, work side by side to push the boundaries of early-stage drug discovery.
This close collaboration across disciplines is central to our approach, enabling us to tackle complex scientific challenges from first principles and translate cutting-edge ideas into novel therapeutic candidates. At AQEMIA, team members are encouraged to contribute their expertise, learn from one another, and play an active role in shaping the future of drug invention.
About This Role As part of the Rocket Launcher team, you’ll play a central role in advancing hit identification, hit expansion, and hit‑to‑lead efforts. You’ll refine and elevate our virtual screening and hit‑optimization pipelines, leveraging a multidisciplinary approach to deliver high‑impact improvements. You’ll partner closely with experts across domains and lead cross‑functional projects that integrate state‑of‑the‑art computational technologies into our discovery workflows.
What You’ll Be Doing
(Note: This position does not involve deep learning methods development.)
You Could Be a Great Fit If
Nice-to-Have:
We will be accepting applications until 7th April. Once the role closes, our team will review all submissions and reach out to candidates selected for interview. Why Join Us ? At AQEMIA, we work for a mission: joining us means having your own impact on changing the way drugs are discovered, and helping to shape the direction of our fast-growing company and team. Expanding Drug Discovery Pipeline : Focused on critical therapeutic areas like Oncology, CNS, Immuno-inflammation... with in vivo proof of concept/patent stage programs. Collaborations with top Pharma, including a $140M Sanofi deal.
World-Class Interdisciplinary Team : work alongside exceptional talent at the intersection of technology and life sciences. Our teams combine deep expertise in AI, physics-based modeling, biology, and medicinal chemistry to push the boundaries of innovation.
DeepTech Recognition : AQEMIA is proud to be part of the French Tech 120 and France 2030 , highlighting our role as a key player in Europe’s DeepTech ecosystem.
Prime Location with Flexibility : Our offices are located in the heart of Paris and London (King’s Cross) , with flexible work arrangements including up to two remote days per week.
Strong Financial Backing : $100M raised from leading European and International investors
We may use artificial intelligence (AI) tools to support parts of the hiring process, such as reviewing applications, analyzing resumes, or assessing responses. These tools assist our recruitment team but do not replace human judgment. Final hiring decisions are ultimately made by humans. If you would like more information about how your data is processed, please contact us.
Your next opportunity is in here somewhere. Sign up to explore 52,000+ startups and their open roles. No spam. No gamification. Just jobs.
52,000+
Startups
66,000+
Open Roles
1,300+
New This Week